ArticleBMC infectious diseases2026
Malondialdehyde, 8-iso-prostaglandin F2α, and lipid profile alterations in COVID-19 patients: insights from South-Western Nigeria.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOxidative stress and lipid metabolism disruptions drive COVID-19 severity, but data from African populations, particularly Nigeria, are limited. This study explored malondialdehyde (MDA), 8-iso-prostaglandin F2α (8-iso-PGF2α), and lipid profile changes in COVID-19 patients in South-Western Nigeria, emphasizing co-infections.
methodsThis cross-sectional study included 60 COVID-19 patients, with and without comorbidities, and 50 healthy controls at three Lagos isolation centers from July to December 2021. Disease severity (mild, moderate, severe) was assessed using clinical, oxygen saturation, and radiologic criteria. Serum MDA and lipid profiles were measured by spectrophotometry, and 8-iso-PGF2α by enzyme-linked immunosorbent assay. ANOVA with Tukey post-hoc tests analyzed normally distributed variables, and Kruskal–Wallis tests evaluated skewed variables. Age-adjusted comparisons used ANCOVA, with log-transformation for non-normal data. Spearman’s correlation assessed relationships between oxidative stress and lipid parameters, with Bonferroni correction for multiple comparisons.
resultsCOVID-19 patients showed elevated MDA, 8-iso-PGF2α, triglycerides, and TG/HDL-C ratios (p ≤ 0.001), and reduced total cholesterol, LDL-C, and HDL-C (p ≤ 0.001) compared to controls. Oxidative stress markers correlated with lipid parameters, suggesting cardiovascular risk. Severe cases and malaria co-infected patients had more pronounced changes, though small subgroup sizes limited findings.
conclusionCOVID-19 in Nigerian patients shows elevated MDA, 8-iso-PGF₂α, and dyslipidaemia (higher triglycerides, TG/HDL-C ratio, lower HDL-cholesterol), worsened by severity and malaria co-infection. These suggest biomarkers for risk stratification and therapy. The cross-sectional design limits causality, requiring larger, prospective studies for metabolic monitoring in co-endemic settings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.